CLEC10A/CD301 Antibody (YA7116)
CLEC10A/CD301 Antibody (YA7116) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CLEC10A/CD301.
-
Host:
Mouse
-
Isotype:
IgG1
-
Application:
FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
Applications
| Application |
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|
| Dilution Ratio | 1:200-1:400 | 1:10000 |
Product Details
CLEC10A/CD301 Antibody (YA7116) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CLEC10A/CD301.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 35.4kDa;
SwissProt: SwissProt: Q8IUN9
Purified recombinant fragment of human CD301 (AA: extra 158-316) expressed in E. Coli.
Endogenous
affinity purified.
Non-conjugated
Unmodified
IgG1
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
CLEC10A/CD301 is a C-type lectin receptor involved in recognition of N-acetylgalactosamine (GalNAc)-terminated glycans by myeloid antigen presenting cells (APCs). Binds in a Ca(2+)-dependent manner to alpha- and beta-linked GalNAc residues on glycoprotein and glycolipid antigens, including alphaGalNAc- and Galbeta1->3GalNAc-O-Ser/Thr also known as Tn and T antigens, LacdiNAc epitope GalNAcbeta1->4GlcNAc and its derivative GalNAcbeta1->4-(Fucalpha1->3)GlcNAc, O-linked core 5 and 6 glycans, and GM2 and GD2 gangliosides. Acts as a signaling receptor at the interface of APC-T cell interactions. On immature dendritic cells, recognizes Tn antigen-carrying PTPRC/CD45 receptor on effector T cells and downregulates PTRPN/CD45 phosphatase activity with an impact on T cell activation threshold, cytokine production and proliferation. Modulates dendritic cell maturation toward a tolerogenic phenotype leading to generation of regulatory CD4-positive T cell subset with immune suppressive functions. Acts as an endocytic pattern recognition receptor involved in antitumor immunity. During tumorigenesis, recognizes Tn antigens and its sialylated forms Neu5Ac-Tn and Neu5Gc-Tn expressed on tumor cell mucins. On immature dendritic cells, can internalize Tn-terminated immunogens and target them to endolysosomal compartment for MHC class I and II antigen presentation to CD8-positive and CD4-positive T cells, respectively[1][2][3][4][5][6][7][8].
-
Subcellular Localization
Cell membrane,Early endosome membrane,Lysosome membrane
-
Expression
Tissue_Specificity: Expressed in myeloid antigen presenting cells in lymph nodes and skin (at protein level). Expressed in dermal dendritic cells (at protein level) -
Isoforms & Post-Translational Modification
Q8IUN9 has three isomers: Q8IUN9-1: 35446 Da (predicted); Q8IUN9-2: 32884 Da (predicted); Q8IUN9-3: 28877 Da (predicted).
-
Subunit
Interacts with A-, B- and C-domain containing PTPRC/CD45 isoforms: isoform 1/CD45ABC, isoform 3/CD45AB, isoform 5/CD45BC and isoform 7/CD45B
-
SwissProt ID
Documentation